Does ARA-290 increase red blood cells like EPO?

No. ARA-290 was specifically engineered to target the innate repair receptor (IRR) — a heteromeric EPOR/βcR complex — rather than the homodimeric EPOR that drives red blood cell production. ARA-290 has minimal affinity for the homodimeric EPOR. No increase in red blood cells, hematocrit, or thrombosis risk was observed in clinical trials. This is the fundamental design advantage of ARA-290 over conventional EPO: tissue-protective and anti-inflammatory effects without the blood-thickening erythropoietic risk.

What did the Phase II sarcoidosis neuropathy trial find?

The Phase II RCT (Brines et al., Molecular Medicine 2014) enrolled 39 patients with sarcoidosis-related small fiber neuropathy. ARA-290 SC for 28 days produced significant pain reduction vs. placebo. Crucially, skin biopsy showed increased intraepidermal nerve fiber density — direct evidence of structural nerve regeneration in humans, not just symptomatic relief. Small nerve fibers that had been lost due to sarcoidosis-driven inflammation structurally regrew during ARA-290 treatment. This is the strongest ARA-290 human evidence.

What is ARA-290 used for in biohacker communities?

ARA-290 is primarily used in condition-specific biohacker communities dealing with neuropathic pain (diabetic neuropathy, small fiber neuropathy, CRPS, sarcoidosis nerve damage). The nerve regeneration mechanism also attracts users interested in nerve repair after injury. Anti-inflammatory effects and beta cell protection attract users managing insulin resistance or chronic inflammatory conditions. It's rarely discussed in general biohacker spaces — the community is concentrated among people who have researched EPO's tissue-protective biology or who have specific neuropathic conditions.

How does ARA-290 differ from BPC-157 for tissue repair?

BPC-157 promotes tissue healing broadly via NO synthesis, growth factor upregulation, and angiogenesis — primarily studied for musculoskeletal and GI tissue. ARA-290 targets specifically the innate repair receptor on neural tissue, cardiomyocytes, renal cells, and immune cells via the EPO receptor system. ARA-290 is the more specific compound for neuropathic conditions and nerve regeneration; BPC-157 is more broadly applicable for physical tissue repair. They operate through different receptor systems and are complementary rather than redundant.

COMPOUND LIBRARY·ARA-290

COMPOUND PROFILE · PEPPERLEDGER

ARA-290

Type

Synthetic cyclic peptide — 11-amino-acid cyclic helix B surface peptide derived from erythropoietin

Class

Tissue-protective peptide · Anti-inflammatory · Neuroprotective — activates EPO's tissue-protective functions via IRR without erythropoietic effects

Administration

Subcutaneous injection · IV (clinical trials)

Half-life

Short plasma half-life; tissue-protective effects via receptor-mediated signaling

Most studied use

Neuropathic pain · Small fiber neuropathy · Sarcoidosis nerve damage · Diabetic neuropathy

Regulatory status

Not FDA-approved · Phase I/II completed for sarcoidosis neuropathy and diabetic neuropathy · Orphan drug designation · Research chemical

Human evidence

Moderate — Phase I/II data confirming neuropathic pain reduction and structural nerve fiber density increase in humans

Preclinical evidence

Moderate — IRR mechanism, anti-inflammatory, and neuroprotective effects confirmed

EDUCATIONAL TOOL — NOT MEDICAL ADVICE

What is ARA-290?

ARA-290 was engineered from erythropoietin (EPO) to isolate its tissue-protective functions from its erythropoietic (red blood cell-producing) functions. EPO receptors exist throughout the body — in neurons, heart, kidneys, immune cells — where EPO activation promotes survival, reduces inflammation, and supports repair. ARA-290 targets the 'innate repair receptor' (IRR), a heteromeric EPOR/βcR complex expressed in non-hematopoietic tissue, without activating the homodimeric EPOR that drives red blood cell production. All the protection, none of the blood-thickening risk.

The human evidence is concentrated in neuropathic pain. A Phase II trial in sarcoidosis patients with small fiber neuropathy showed ARA-290 significantly reduced pain scores — and crucially, increased intraepidermal nerve fiber density on skin biopsy. This is direct evidence of structural nerve regeneration in humans, not just symptomatic relief. A diabetic neuropathy Phase II trial showed improved pain scores alongside improved HbA1c — suggesting concurrent metabolic benefit.

For biohackers, ARA-290 occupies a specific niche: neuropathic pain management, nerve regeneration support, anti-inflammatory effects for chronic inflammatory conditions, and potentially metabolic improvement via beta cell protection. It's rarely discussed in mainstream biohacker spaces but has a devoted community among people who have researched EPO's tissue-protective biology or who are dealing with chronic neuropathic conditions.

How it works

Innate Repair Receptor (IRR) Activation

ARA-290 binds the IRR — a heteromeric complex of one EPO receptor subunit and one beta-common receptor (βcR) subunit — expressed in neurons, cardiomyocytes, renal cells, beta cells, and immune cells. Activation drives JAK2/STAT5 and PI3K/Akt pro-survival signaling. Critically, this receptor configuration does not drive erythropoiesis — that requires the homodimeric EPOR that ARA-290 has minimal affinity for.

Neuroprotection and Structural Nerve Regeneration

In peripheral nerves: promotes Schwann cell survival, stimulates axonal regeneration, reduces neuroinflammation. The Phase II increase in intraepidermal nerve fiber density confirms structural regeneration in humans — small fibers lost due to sarcoidosis-driven inflammation regrew during ARA-290 treatment. This is the strongest and most clinically meaningful finding from the ARA-290 evidence base.

Anti-Inflammatory Mechanism

Promotes M2 anti-inflammatory macrophage polarization, reduces NF-κB and downstream cytokines (TNF-α, IL-1β, IL-6). Broad anti-inflammatory effect across IRR-expressing tissues — potentially relevant beyond neuropathic conditions for anyone managing chronic low-grade inflammation.

Metabolic Beta Cell Protection

IRR expression on pancreatic beta cells: ARA-290 protects them from inflammatory damage and may improve insulin sensitivity. The HbA1c improvement in the diabetic neuropathy trial suggests functional metabolic benefit alongside the neuroprotective effects — though whether this is direct beta cell protection or secondary to reduced inflammation requires further study.

What the research shows

STUDYMolecular Medicine · 2013

ARA-290 improves symptoms and increases corneal nerve fiber density in sarcoidosis small-fiber neuropathy

Dahan A et al.

Sarcoidosis patients with documented small-fiber neuropathy. 28 days of daily subcutaneous ARA-290 vs. placebo produced a significant increase in corneal small-nerve-fiber density (corneal confocal microscopy), alongside improved neuropathic symptoms, thermal sensitivity, and 6-minute-walk distance. Structural nerve-fiber gain — the strongest human ARA-290 evidence.

View on PubMed →

STUDYMolecular Medicine · 2012

Safety and efficacy of ARA-290 in sarcoidosis small-fiber neuropathy — randomized, double-blind pilot

Heij L et al.

Randomized, double-blind pilot — 22 sarcoidosis patients with small-fiber-neuropathy symptoms (12 ARA-290, 10 placebo). The ARA-290 group showed significant improvement in the Small Fiber Neuropathy Screening List (SFNSL) score at week 4 and in pain and physical-functioning quality-of-life measures, with a favorable safety profile. First controlled human signal.

View on PubMed →

WHAT THE RESEARCH SHOWS

✓KNOWN

✓IRR activation without erythropoiesis — mechanistically confirmed, no hematocrit increase in trials
✓Intraepidermal nerve fiber density increase in Phase II — structural human nerve regeneration
✓Neuropathic pain reduction in Phase II RCTs — sarcoidosis and diabetic neuropathy
✓Anti-inflammatory macrophage polarization and cytokine reduction

?UNCERTAIN

?Long-term nerve regeneration maintenance after stopping
?Anti-inflammatory effects at biohacker doses vs. trial doses
?Metabolic benefits in non-diabetic, non-neuropathic users
?Optimal duration and frequency for nerve regeneration

What the community reports

—Neuropathic pain reduction — most important reported effect; users with chronic nerve pain report significant relief consistent with the Phase II data

—Gradual improvement over weeks — not immediate; nerve regeneration takes time; most users report peak benefit at 3–4 weeks into a course

—Anti-inflammatory benefits beyond nerve pain in some users — reduced systemic inflammation markers

—Metabolic improvements (glucose management) in insulin-resistant users

—Very clean safety profile — no erythropoietic effects; well-tolerated in trials; community reports match

Common misconceptions

"ARA-290 thickens the blood like EPO."

REALITY

ARA-290 targets IRR, not the homodimeric EPOR that drives erythropoiesis. No increase in red blood cells, hematocrit, or thrombosis risk observed in trials. The risk profile is completely different from conventional EPO — this was the entire design intent.

"ARA-290 is a performance enhancer like EPO."

REALITY

EPO increases endurance via more red blood cells and oxygen delivery. ARA-290 doesn't increase red blood cells — it has tissue-protective, anti-inflammatory, and neuroprotective effects. Not a performance compound in the EPO sense. Different receptor, different biological outcome.

NEUROPROTECTIVE PEPTIDE COMPARISON

ARA-290: EPO-derived, IRR activation, nerve regeneration + anti-inflammatory. Best for neuropathic pain and nerve repair. BPC-157: broad tissue repair, GI + musculoskeletal + neural via NO/growth factors. Cerebrolysin: BDNF/NGF mimicry, 150+ clinical trials, CNS-focused neuroprotection. LL-37: antimicrobial + anti-inflammatory via different immune pathways.

RECONSTITUTION CALCULATOR

Peptide in vial (mg)BAC water (mL)Desired dose (mcg)

EDUCATIONAL TOOL — NOT MEDICAL ADVICE · VERIFY WITH YOUR CLINICIAN

AI RESEARCHER PREVIEW

I have diabetic neuropathy. How should I structure an ARA-290 protocol and what should I track?

The Phase II data gives a good starting framework for protocol design — let me walk through it and adapt it for ongoing tracking. The clinical protocol from the Brines/Dahan trials: 4 mcg/kg SC daily for 28 days. For an 80 kg person, that's approximately 320 mcg per day. This is the most evidence-based approach — it maps directly to what produced both pain reduction and improved HbA1c in the diabetic neuropathy trial. Timeline of expectations: Nerve pain reduction typically begins 1–2 weeks in, with peak benefit around week 3–4 of the course. Nerve regeneration (structural changes like nerve fiber density) takes longer — weeks to months of sustained signaling. Don't evaluate this compound by day 5. What to track for neuropathic pain: Establish a baseline before injection #1. Use a consistent daily pain scale (0-10) at the same time of day. Rate burning, tingling, and numbness separately — these often change at different rates. Track functional capacity: what can you do now that was difficult before? Weekly: fasting glucose and postprandial glucose if you're monitoring the metabolic component — the HbA1c improvement in the trial suggests real beta cell/insulin sensitivity benefit. After the 28-day course: repeat your baseline assessments. If improvement is meaningful, plan a second course 4-6 weeks later. Repeat courses 2–4 times per year is the community standard. Is your neuropathy primarily pain, loss of sensation, or both? That affects which symptoms to prioritize in your tracking.

CONTINUE IN THE APP

Open PepperLedger to track your ARA-290 protocol →

Free to join. No credit card. Ask the Researcher about your neuropathy management protocol once you're in.

Free to join · No credit card · 23-day Pro trial included

Authoritative sources

Registered trials and extra catalog links. These are not Study cards — a registry page is not proof of efficacy.

ClinicalTrials.gov · completed · NCT02039687
ARA 290 for sarcoidosis neuropathy
ClinicalTrials.gov · completed · NCT02070783
Cognitive and neural effects of ARA290